These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38396273)

  • 1. Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer.
    Zhou C; Zhao S; Zhang Y; Cheng J; Shi J; Du G
    Small; 2024 Jul; 20(30):e2310565. PubMed ID: 38396273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Treatment of Triple-Negative Breast Cancer Through Gambogic Acid-Loaded Mesoporous Polydopamine.
    Liu J; Liu H; Huang S; Peng H; Li J; Tu K; Tan S; Xie R; Lei L; Yue Q; Gao H; Cai L
    Small; 2024 Aug; 20(31):e2309583. PubMed ID: 38446095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Biological Evaluation of Novel
    Song X; Gan Q; Zhang X; Zhang J
    Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomimetic Nanomodulators With Synergism of Photothermal Therapy and Vessel Normalization for Boosting Potent Anticancer Immunity.
    Lan J; Zeng R; Li Z; Yang X; Liu L; Chen L; Sun L; Shen Y; Zhang T; Ding Y
    Adv Mater; 2024 Oct; 36(40):e2408511. PubMed ID: 39180264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A T-rojan horse strategy for cancer immunotherapy.
    Rafie C; Pillai A
    Sci Immunol; 2021 May; 6(59):. PubMed ID: 33963062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polydopamine-based nanoplatform for photothermal ablation with long-term immune activation against melanoma and its recurrence.
    Li M; Guo R; Wei J; Deng M; Li J; Tao Y; Li M; He Q
    Acta Biomater; 2021 Dec; 136():546-557. PubMed ID: 34536603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
    Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
    Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
    Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
    Chen F; Liu C; Zhang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.
    Lelliott EJ; Kong IY; Zethoven M; Ramsbottom KM; Martelotto LG; Meyran D; Zhu JJ; Costacurta M; Kirby L; Sandow JJ; Lim L; Dominguez PM; Todorovski I; Haynes NM; Beavis PA; Neeson PJ; Hawkins ED; McArthur GA; Parish IA; Johnstone RW; Oliaro J; Sheppard KE; Kearney CJ; Vervoort SJ
    Cancer Discov; 2021 Oct; 11(10):2582-2601. PubMed ID: 33990344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
    Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
    Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.
    Oh SJ; Cho H; Kim S; Noh KH; Song KH; Lee HJ; Woo SR; Kim S; Choi CH; Chung JY; Hewitt SM; Kim JH; Baek S; Lee KM; Yee C; Park HC; Kim TW
    Cancer Res; 2018 May; 78(10):2638-2653. PubMed ID: 29437706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing antitumor immunity with stimulus-responsive mesoporous silicon in combination with chemotherapy and photothermal therapy.
    Chen S; Huang R; Shen F; Wu Y; Lin Y; Yang X; Shen J; Fang Y
    Biomater Sci; 2024 Jul; 12(15):3826-3840. PubMed ID: 38758027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment.
    Ji Y; Liu X; Li J; Xie X; Huang M; Jiang J; Liao YP; Donahue T; Meng H
    Nat Commun; 2020 Aug; 11(1):4249. PubMed ID: 32843618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.